Aggressive/Intermediate Grade
Survivors of Some Childhood Cancers May Face Cognitive Impairment
(05/18/2010)
Survivors of non-central nervous system (CNS) childhood cancers reported a statistically and clinically significantly higher rate of neurocognitive impairment than their cancer-free siblings, according to the results of a study published in the Journal of the National Cancer Institute.
Highly Aggressive/High Grade
Survivors of Some Childhood Cancers May Face Cognitive Impairment
(05/18/2010)
Survivors of non-central nervous system (CNS) childhood cancers reported a statistically and clinically significantly higher rate of neurocognitive impairment than their cancer-free siblings, according to the results of a study published in the Journal of the National Cancer Institute.
Indolent/Low Grade
Maintenance Therapy with Rituxan Prolongs Lymphoma Remission
(05/26/2010)
Among patients with follicular lymphoma who responded to initial treatment with chemotherapy and Rituxan® (rituximab), those who received an additional two years of Rituxan as maintenance therapy remained free of lymphoma progression for longer than patients who did not receive maintenance therapy. The results of this Phase III clinical trial will be presented at the 2010 annual meeting of the American Society of Clinical Oncology.
Mantle Cell
Survivors of Some Childhood Cancers May Face Cognitive Impairment
(05/18/2010)
Survivors of non-central nervous system (CNS) childhood cancers reported a statistically and clinically significantly higher rate of neurocognitive impairment than their cancer-free siblings, according to the results of a study published in the Journal of the National Cancer Institute.
Recurrent
Survivors of Some Childhood Cancers May Face Cognitive Impairment
(05/18/2010)
Survivors of non-central nervous system (CNS) childhood cancers reported a statistically and clinically significantly higher rate of neurocognitive impairment than their cancer-free siblings, according to the results of a study published in the Journal of the National Cancer Institute.
T-Cell
Istodax Active against Refractory Cutaneous T-cell Lymphoma
(08/31/2010)
Final results from a Phase II clinical trial provide additional evidence that Istodax® (romidepsin) is active against refractory cutaneous T-cell lymphoma. These results were published in the Journal of Clinical Oncology.
Survivors of Some Childhood Cancers May Face Cognitive Impairment
(05/18/2010)
Survivors of non-central nervous system (CNS) childhood cancers reported a statistically and clinically significantly higher rate of neurocognitive impairment than their cancer-free siblings, according to the results of a study published in the Journal of the National Cancer Institute.